Pharmacokinetics and tolerance of zidovudine in preterm infants

Journal of Pediatrics

Volumn 142, Issue 1, 2003, Pages 47-52

  Capparelli, Edmund V ^{a,b,c,d,e,f,g,h}   Mirochnick, Mark ^{a,b,c,d,e,f,g}   Dankner, Wayne M ^{a,b,c,d,e,f,g}   Blanchard, Suzette ^{a,b,c,d,e,f,g}   Mofenson, Lynne ^{a,b,c,d,e,f,g}   McSherry, George D ^{a,b,c,d,e,f,g}   Gay, Hannah ^{a,b,c,d,e,f,g}   Ciupak, Gregory ^{a,b,c,d,e,f,g}   Smith, Betsy ^{a,b,c,d,e,f,g}   Connor, James D ^{a,b,c,d,e,f,g}   David, Elmer ⁱ   Stephens, Richard ⁱ   Wei, Tzong Jer ⁱ   Hoyt, Mary Jo ⁱ   Barlow, Beth ^j   Sadler, Sondra ^j   Naylor, Stacee ^j   Petru, Ann ^k   McKinney, Ross ^c   Ferguson, Lori ^c   Valentine, Megan ^c   Hurwitz, Jean ^c   Squires, Janet ^l   Johnson, George ^m   Clarken, Moya ^m   Kovacs, Andrea ⁿ   Pelton, Steven ^o   Melvin, Ann ^p   Frenkel, Lisa ^p   Mohan, Kathleen ^p   O'Hara, Mary Jo ^p   Wade, Nancy ^q   Lepow, Martha ^q   Hughes, Patricia ^q   Horgan, Michael ^q   Levy, Louis ^r   Dobson, F Moncrief ^r   Clarke Steffen, Laura ^s   Piatt, Janice ^s   Cunningham, Coleen ^t   Contello, Kathie ^t   Barr, Emily ^t   Famiglietti, Maureen ^t   Sleasman, John ^u   Rathmore, Mobeen ^v   Khayat, Abeer ^v   Eagle, Michelle ^v   Mahmoudi, Saniyyah ^v   Jimenez, Eleanor ^w   Englund, Janet ^x   Lofton, Pamela ^x   Elsen, Christine ^x   Oram, Ronda ^x   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^h Children's Hospital ^*  (United States)

ⁱ UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^j UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^k CHILDREN S HOSPITAL OAKLAND   (United States)

^l CHILDREN S MEDICAL CENTER   (United States)

^m MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁿ LAC USC MEDICAL CENTER   (United States)

^o BOSTON MEDICAL CENTER   (United States)

^p SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^q ALBANY MEDICAL CENTER   (United States)

^r Pediatric Center   (United States)

^s PHOENIX CHILDREN'S HOSPITAL   (United States)

^t SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^u UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^v UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^w UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^x UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FUROSEMIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TOLERANCE; FEMALE; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; MALE; MULTICENTER STUDY; PREMATURITY; PRIORITY JOURNAL;

EID: 0037238447     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2003.mpd0335     Document Type: Article

References (20)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads of <1000 copies/mL. J Infect Dis 2001;183:539-45.
3. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000;343:982-91.
4. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.
5. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795-802.
6. Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine: an update. Clin Pharmacokinet 1996;30:251-62.
7. Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, et al. Phase I evaluation of zidovudine administrated to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993;122:1137-44.
8. Mirochnick M, Capparelli EV, Connor JD. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Therap 1999;66:16-24.
9. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants. Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (Protocol 082). Am J Obstet Gynecol 1993;168:1510-6.
10. Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KHP, et al. Pharmacokinetics of zidovudine and lamuvidine in neonates following co-administration of oral doses every 12 hours. J Clin Pharmacol 2001; 41:732-41.
11. Reiter PD, Stiles AD. Lorazepam toxicity in a premature infant. Ann Pharmacother 1993;27:727-9.
12. Bhat R, Chari G, Gulati A, Aldana O, Velamat, R, Bhargava H. Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. Clin Pharmocol Ther 1992;51:334-42.
13. Mirochnick M, Capparelli E, Dankner W, Sperling RS, Van Dyke R, Spector S. Zidovudine pharmacokinetics in premature infants exposed to HIV. Antimicrob Agent Chemother 1998;42:808-12.
14. Balis FM, Pizzo PA, Murphy RF, Eddy J, Jarosinski PF, Falloon J, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.
15. Blanche S, Tardieu M, Rustin P, Slama A, Barter B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
16. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intens Care Med 1998;24:247-50.
17. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM users' guides part I-VII technical report. University of San Francisco (CA); 1992-1998.
18. Abrams EJ, Matheson PB, Thomas PA, Thea DM, Krasinski K, Lambert G, et al. New York City Perinatal HIV Transmission Collaborative Study Group. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics 1995;96:451-8.
19. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001;41:927-34.
20. Kuhn L, Steketee RW, Weedon J, Abrams EJ, Lambert G, Bamji M, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. J Infect Dis 1999;179:52-8.